STOCK TITAN
  1. Home
  2. News
  3. RYTM

Rhythm Pharmaceuticals Inc. - RYTM STOCK NEWS

Welcome to our dedicated news page for Rhythm Pharmaceuticals (Ticker: RYTM), a resource for investors and traders seeking the latest updates and insights on Rhythm Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rhythm Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rhythm Pharmaceuticals's position in the market.

News
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. granted inducement equity grants to four new employees, consisting of inducement stock options and inducement restricted stock units. The grants cover an aggregate of 13,020 shares of its common stock. The stock options have an exercise price of $42.52 per share and will vest over a three-year period. The RSUs will vest over four years. These grants are subject to the terms of the Inducement Plan adopted by Rhythm's board of directors on February 9, 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) has entered into a global licensing agreement with LG Chem, Ltd. for LB54640, an investigational oral small molecule melanocortin-4 receptor (MC4R) agonist now in Phase 2 clinical trials. The Phase 1 trial in healthy overweight adults demonstrated dose-dependent weight reduction and a favorable safety profile. LB54640 has received orphan drug designation from the U.S. Food and Drug Administration for leptin receptor (LEPR) deficiency and proopiomelanocortin(POMC). Rhythm will sponsor two Phase 2 studies to evaluate weight loss efficacy, safety, tolerability, and pharmacokinetics of LB54640.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
acquisition
-
News
Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
Rhea-AI Summary
Rhythm Pharmaceuticals, a global commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases, provided a business update. The company completed screening for enrollment in a pivotal, Phase 3 clinical trial evaluating setmelanotide in patients with acquired hypothalamic obesity. Rhythm anticipates overenrolling the trial with over 140 patients consented. The top-line study results are expected in H1 2025. Positive reimbursement decisions were achieved in Spain for IMCIVREE to treat patients with Bardet-Biedl syndrome and POMC/LEPR deficiencies. Additionally, the FDA accepted the IND application for RM-718, a new, weekly treatment designed to be more targeted and potent than setmelanotide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
clinical trial
News
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced the grant of inducement equity grants to a new employee, consisting of stock options and restricted stock units. The options have an exercise price of $38.00 per share and will vest over a period of three years, while the RSUs will vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) sponsors the second annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) in Paris, France. The event will highlight new scientific developments for rare MC4R pathway diseases, with over 50 poster presentations and approximately 150 healthcare professionals from 20 countries expected to attend.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
News
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced positive results from its Phase 3 trial evaluating setmelanotide in pediatric patients ages 2-<6yo. The trial achieved the primary endpoint with a 3.04 mean reduction in BMI-Z score and an 18.4 percent mean reduction in BMI in patients with obesity due to POMC/LEPR deficiency or BBS. RM-718 also showed potential to reduce body weight and hyperphagia with no off-target cardiovascular effects. Responder rates of 25 to 56 percent were demonstrated in six genetic cohorts of Phase 2 DAYBREAK trial of setmelanotide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none
News
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) announced the grant of inducement equity grants to two new employees through inducement stock options and restricted stock units, subject to the terms of the Inducement Plan. The stock options have an exercise price of $27.42 per share and will vest over a period of three years, while the RSUs will vest over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.33%
Tags
none
-
News
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
Rhea-AI Summary
Rhythm Pharmaceuticals, Inc. reported a net revenue of $22.5 million from global sales of IMCIVREE in Q3 2023, with over 100 international patients on reimbursed IMCIVREE therapy. They also achieved a 25.5% mean BMI reduction in patients with hypothalamic obesity on setmelanotide therapy. The company has a cash on-hand of $299.3 million and plans to provide an R&D update on December 6.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
earnings
-
News
Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)
Rhea-AI Summary
Rhythm Pharmaceuticals announced that CADTH has recommended reimbursement for weight management in patients with obesity due to Bardet-Biedl syndrome (BBS). The recommendation is based on the positive results from Rhythm's Phase 3 trial, which showed a reduction in weight-related parameters. BBS is a rare genetic disease with an estimated prevalence of 1 in 100,000 to 160,000 in North America and Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
News
Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
Rhea-AI Summary
Rhythm Pharmaceuticals will host a live conference call to report its Q3 2023 financial results and provide a corporate update. The CEO will also participate in a fireside chat at the Stifel Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
conferences earnings
Stock RYTM logo
Rhythm Pharmaceuticals Inc.

Nasdaq:RYTM

RYTM Rankings

#1738 Ranked by Market Cap
#2878 Ranked by Stock Gains
N/A Ranked by Dividends

RYTM Stock Data

2.43B
44.99M
0.52%
112.26%
16.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Boston

About RYTM

rhythm pharmaceuticals inc. is a biotechnology company located in 855 boylston street, 11th floor, boston, ma, united states.